Skip to main navigation
menu
  • Vision and Leadership
  • Science and Pipeline
    • « Back
    • Science
    • Pipeline
    • Clinical Studies
    • Partners
  • Commitment
  • Investors
    • « Back
    • Site - Investor Relations - 1st Tier

    • Overview
    • Stock Information
      • « Back
      • Stock Quote
      • Analyst Coverage
    • News & Events
      • « Back
      • Press Releases
      • Presentations & Events
    • Governance
      • « Back
      • Governance
      • Committee Composition
    • Financials
      • « Back
      • SEC Filings
      • Reports & Results
    • Investor Resources
      • « Back
      • FAQs
      • Scientific Presentations
      • Email Alerts
      • RSS Feeds
  • People
  • Contact
  • Vision and Leadership
  • Science and Pipeline
    • « Back
    • Science
    • Pipeline
    • Clinical Studies
    • Partners
  • Commitment
  • Investors
    • « Back
    • Site - Investor Relations - 1st Tier

    • Overview
    • Stock Information
      • « Back
      • Stock Quote
      • Analyst Coverage
    • News & Events
      • « Back
      • Press Releases
      • Presentations & Events
    • Governance
      • « Back
      • Governance
      • Committee Composition
    • Financials
      • « Back
      • SEC Filings
      • Reports & Results
    • Investor Resources
      • « Back
      • FAQs
      • Scientific Presentations
      • Email Alerts
      • RSS Feeds
  • People
  • Contact

for investors

Ovid Hosts Conference Call to Discuss Strategic Transaction
Mar 3, 2021 8:30 AM EST
Click here for webcast

Site - Investor Relations - 2nd Tier

  • Overview
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Presentations & Events
  • Governance
    • Governance
    • Committee Composition
  • Financials
    • SEC Filings
    • Reports & Results
  • Investor Resources
    • FAQs
    • Scientific Presentations
    • Email Alerts
    • RSS Feeds

Site - Investor Relations - 3rd Tier

  • Overview
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Presentations & Events
  • Governance
    • Governance
    • Committee Composition
  • Financials
    • SEC Filings
    • Reports & Results
  • Investor Resources
    • FAQs
    • Scientific Presentations
    • Email Alerts
    • RSS Feeds

Press Releases

Press Releases

  • Apr 20, 2021 Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
  • Apr 19, 2021 OVID Provides Update on OV101 Program and the Prioritization of its Resources
  • Mar 30, 2021 Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
  • Mar 15, 2021 Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
  • Mar 03, 2021 Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Site - Stockholder Tools

Print Page RSS Feeds Share Page E-mail Alerts

Site - Footer Nav

  • Contact
  • Privacy Policy
  • Terms & Conditions Agreement
  • Community Guidelines
  • Third-Party Websites

    Site - Footer - Social icons

    • Linkedin
    • Twitter
    • Webcast
    • Youtube
    • Facebook
© Copyright 2021 Ovid Therapeutics.
Ovid, Ovid Therapeutics, Ovid Therapeutics Inc., and BoldMedicine are trademarks of Ovid Therapeutics Inc. All rights reserved.

    Site - Footer - Social icons

    • Linkedin
    • Twitter
    • Webcast
    • Youtube
    • Facebook
  • Share on:

  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Digg
  • Google
  • StumbleUpon
  • What's This?
    Share this page through your favorite social channel or email this page to a colleague.